{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-013283","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2024-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.305912+00:00","generated_at":"2026-06-03T06:21:52.560831+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vistagen announces positive Phase 2A results for PH15 nasal spray improving psychomotor impairment from mental fatigue","bullets":["PH15 nasal spray demonstrated statistically significant improvement in reaction time versus placebo and caffeine (p<0.001) in sleep-deprived participants.","Phase 2A pilot study (2011, acquired via Pherin in February 2023) enrolled 10 participants in a crossover design.","PH15 was safe and well-tolerated; adverse events comparable to placebo, with brief nasal itching in one subject.","CEO Shawn Singh highlighted potential for shift work disorder, sleep apnea, and narcolepsy patients.","No serious adverse events reported; caffeine group experienced palpitations, euphoria, dry mouth, stomachache, and polyuria."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-013283","json":"https://secwatch.observer/filing/0001437749-24-013283.json","markdown":"https://secwatch.observer/filing/0001437749-24-013283.md","text":"https://secwatch.observer/filing/0001437749-24-013283.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000143774924013283/0001437749-24-013283-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000143774924013283/vtgn20240425_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T06:21:52.560831+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}